RESUMEN
BACKGROUND: Current clinical care for common bacterial STIs (Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG) and Mycoplasma genitalium (MG)) involves empiric antimicrobial therapy when clients are symptomatic, or if asymptomatic, waiting for laboratory testing and recall if indicated. Near-to-patient testing (NPT) can improve pathogen-specific prescribing and reduce unnecessary or inappropriate antibiotic use in treating sexually transmitted infections (STI) by providing same-day delivery of results and treatment. METHODS: We compared the economic cost of NPT to current clinic practice for managing clients with suspected proctitis, non-gonococcal urethritis (NGU), or as an STI contact, from a health provider's perspective. With a microsimulation of 1000 clients, we calculated the cost per client tested and per STI- and pathogen- detected for each testing strategy. Sensitivity analyses were conducted to assess the robustness of the main outcomes. Costs are reported as Australian dollars (2023). RESULTS: In the standard care arm, cost per client tested for proctitis, NGU in men who have sex with men (MSM) and heterosexual men were the highest at $247.96 (95% Prediction Interval (PI): 246.77-249.15), $204.23 (95% PI: 202.70-205.75) and $195.01 (95% PI: 193.81-196.21) respectively. Comparatively, in the NPT arm, it costs $162.36 (95% PI: 161.43-163.28), $158.39 (95% PI: 157.62-159.15) and $149.17 (95% PI: 148.62-149.73), respectively. Using NPT resulted in cost savings of 34.52%, 22.45% and 23.51%, respectively. Among all the testing strategies, substantial difference in cost per client tested between the standard care arm and the NPT arm was observed for contacts of CT or NG, varying from 27.37% to 35.28%. CONCLUSION: We found that NPT is cost-saving compared with standard clinical care for individuals with STI symptoms and sexual contacts of CT, NG, and MG.
Asunto(s)
Enfermedades de Transmisión Sexual , Humanos , Masculino , Femenino , Enfermedades de Transmisión Sexual/diagnóstico , Enfermedades de Transmisión Sexual/economía , Enfermedades de Transmisión Sexual/tratamiento farmacológico , Gonorrea/diagnóstico , Gonorrea/economía , Gonorrea/tratamiento farmacológico , Australia , Adulto , Análisis Costo-Beneficio , Infecciones por Chlamydia/diagnóstico , Infecciones por Chlamydia/economía , Infecciones por Chlamydia/tratamiento farmacológico , Chlamydia trachomatis , Neisseria gonorrhoeae/aislamiento & purificación , Mycoplasma genitalium , Tamizaje Masivo/economía , Tamizaje Masivo/métodos , Infecciones por Mycoplasma/diagnóstico , Infecciones por Mycoplasma/tratamiento farmacológico , Infecciones por Mycoplasma/economía , Uretritis/diagnóstico , Uretritis/economía , Uretritis/tratamiento farmacológico , Uretritis/microbiologíaRESUMEN
BACKGROUND Urogenital bacterial infections have a high incidence in humans. The most frequent cause of infections of the urogenital tract is gram-negative bacteria. Antibiotics are very effective in curing infectious diseases but they are accompanied by health complications. Probiotics are live microorganisms that are believed to confer a beneficial effect on human health when consumed in adequate amounts. This study aimed to compare outcomes from antibiotic treatment with and without the use of probiotics in 897 patients with lower urogenital tract infections, including cystitis, urethritis, prostatitis, and vulvovaginitis. MATERIAL AND METHODS A total of 897 patients aged 18 to 55 years were included in this research. Patients were divided into an intervention group including 460 patients (254 women, 206 men) and a comparison group including 437 patients (240 women, 197 men). The probiotics received by patients were capsules of ProBalans®. The diagnosis of cystitis, urethritis, prostatitis, vulvovaginitis, and sexually transmitted infection was done using several tests, and antibiotics were used for treatment. Qualitative data were analyzed using the chi-square or Fisher exact test. RESULTS We found a significant difference regarding patients' impressions of improvement after therapy between patients in the intervention group and the comparison group. CONCLUSIONS Use of probiotics together with antibiotics in the treatment of urogenital tract infection can help to reduce the adverse effects of antibiotics, increase the efficiency of antibiotic therapy, and reduce bacterial resistance to antibiotics. However, further research is needed to confirm these potential health benefits.
Asunto(s)
Antibacterianos , Cistitis , Probióticos , Prostatitis , Uretritis , Vulvovaginitis , Humanos , Adulto , Probióticos/uso terapéutico , Masculino , Femenino , Persona de Mediana Edad , Antibacterianos/uso terapéutico , Cistitis/tratamiento farmacológico , Adolescente , Adulto Joven , Prostatitis/tratamiento farmacológico , Prostatitis/microbiología , Uretritis/tratamiento farmacológico , Uretritis/microbiología , Vulvovaginitis/tratamiento farmacológico , Vulvovaginitis/microbiología , Resultado del Tratamiento , Infecciones Urinarias/tratamiento farmacológicoRESUMEN
Mycoplasma genitalium (M. genitalium) poses a significant public health challenge due to its association with non-gonococcal urethritis (particularly in men) and antimicrobial resistance. However, despite the prevalence of M. genitalium infections and the rise in resistance rates, routine testing and surveillance remain limited. This is the first study from Croatia that aimed to assess the prevalence and trends of resistance in M. genitalium strains isolated from male individuals by detecting macrolide and fluoroquinolone resistance genes. The study also aimed to explore the factors associated with resistance and changes in resistance patterns over time. Urine samples collected from male individuals in the Zagreb County and northwest region of Croatia between 2018 and 2023 were tested for M. genitalium with the use of molecular methods. Positive samples were subjected to DNA extraction and multiplex tandem polymerase chain reaction (MT-PCR) targeting genetic mutations associated with macrolide (23S rRNA gene) and fluoroquinolone (parC gene) resistance. Of the 8073 urine samples tested from 6480 male individuals (and following the exclusion of repeated specimens), we found that the prevalence of M. genitalium infection was 2.2%. Macrolide resistance was observed in 60.4% of strains, while fluoroquinolone resistance was found in 19.2%. Co-resistance to both antibiotics was present in 18.2% of cases. A statistically significant increase in fluoroquinolone resistance was noted over the study period (p = 0.010), but this was not evident for azithromycin resistance (p = 0.165). There were no statistically significant differences in resistance patterns between age groups, whereas re-testing of patients revealed dynamic changes in resistance profiles over time. The high burden of macrolide resistance and increasing fluoroquinolone resistance underscore the urgent need for comprehensive resistance testing and surveillance programs. The implementation of resistance-guided treatment strategies, along with enhanced access to molecular diagnostics, is pivotal for effectively managing M. genitalium infections.
Asunto(s)
Antibacterianos , Farmacorresistencia Bacteriana , Fluoroquinolonas , Macrólidos , Infecciones por Mycoplasma , Mycoplasma genitalium , Mycoplasma genitalium/genética , Mycoplasma genitalium/efectos de los fármacos , Mycoplasma genitalium/aislamiento & purificación , Humanos , Masculino , Fluoroquinolonas/farmacología , Fluoroquinolonas/uso terapéutico , Croacia/epidemiología , Macrólidos/farmacología , Macrólidos/uso terapéutico , Adulto , Infecciones por Mycoplasma/microbiología , Infecciones por Mycoplasma/epidemiología , Infecciones por Mycoplasma/tratamiento farmacológico , Infecciones por Mycoplasma/orina , Antibacterianos/farmacología , Antibacterianos/uso terapéutico , Farmacorresistencia Bacteriana/genética , Persona de Mediana Edad , Adulto Joven , ARN Ribosómico 23S/genética , Adolescente , Uretritis/microbiología , Uretritis/epidemiología , Uretritis/tratamiento farmacológico , Pruebas de Sensibilidad MicrobianaRESUMEN
BACKGROUND: Mycoplasma genitalium is a major contributor to persistent/recurrent urethritis cases. However, there are limited published studies on recent trends of persistent/recurrent urethritis. METHODS: A retrospective analysis was conducted of men presenting with symptomatic urethritis in 16 sexually transmitted disease (STD) clinics from 2015 to 2019. Poisson regression was used to assess trends in the annual proportions of urethritis episodes with follow-up (FU) characterized with persistent/recurrent urethritis symptoms. Results were also stratified by results of chlamydia (CT) and gonorrhea (NG) testing and treatment prescribed. RESULTS: There were 99,897 urethritis episodes, from 67,546 unique men. The proportion of episodes with persistent/recurrent symptomatic FU visits increased 50.8% over a 4-year period (annual percentage change [APC], 11.3%; 95% confidence interval [CI], 6.5-16.3). Similar trends were observed in nonchlamydial nongonococcal urethritis episodes (APC, 12.7%; 95% CI, 6.8-18.9) but increases among those positive for NG (APC, 12.1%; 95% CI, -2.3 to -28.5) or for CT (APC, 7.3%; 95% CI, -6.7 to 23.5) were not statistically significant. Among episodes who received azithromycin as first-line treatment, increases in the proportion of persistent/recurrent FU visits were observed (APC, 12.6%; 95% CI, 8.6-16.7). For episodes where first-line treatment was doxycycline, no significant increases were detected (APC, 4.3%; 95% CI, -0.3 to 9.2). CONCLUSIONS: We found an increase in the proportion of urethritis episodes with persistent or recurrent symptoms over time. Given these observed trends in episodes negative for NG or CT, an etiology not detectable by routine diagnostics was a likely factor in increased persistence, suggesting patients with urethritis may benefit from diagnostic testing for M. genitalium during an initial symptomatic presentation.
Asunto(s)
Infecciones por Mycoplasma , Mycoplasma genitalium , Recurrencia , Uretritis , Humanos , Uretritis/tratamiento farmacológico , Uretritis/diagnóstico , Uretritis/microbiología , Uretritis/epidemiología , Masculino , Mycoplasma genitalium/aislamiento & purificación , Infecciones por Mycoplasma/tratamiento farmacológico , Infecciones por Mycoplasma/diagnóstico , Infecciones por Mycoplasma/epidemiología , Estudios Retrospectivos , Adulto , Gonorrea/tratamiento farmacológico , Gonorrea/diagnóstico , Gonorrea/epidemiología , Adulto Joven , Infecciones por Chlamydia/tratamiento farmacológico , Infecciones por Chlamydia/diagnóstico , Infecciones por Chlamydia/epidemiología , Antibacterianos/uso terapéutico , Persona de Mediana Edad , Enfermedades de Transmisión Sexual/tratamiento farmacológico , Enfermedades de Transmisión Sexual/diagnóstico , Enfermedades de Transmisión Sexual/epidemiología , Azitromicina/uso terapéutico , Azitromicina/administración & dosificación , Adolescente , Doxiciclina/uso terapéuticoRESUMEN
The occurrence of cysts and papulopustules along the midline penile raphe, as a complication of gonococcal urethritis, is considered an exceptional presentation. These lesions are related to developmental abnormalities in the fusion of the lower portion of the ventral abdominal wall during embryogenesis, which create small pathways along the raphe of the penis, prone to secondary infection in the presence of gonococcal urethritis. We present the case of a 25-year-old male who experienced these lesions twice, coinciding with two separate episodes of gonococcal urethritis following unprotected sex. Treatment with intramuscular ceftriaxone resolved both the urethritis and cystic lesions.
Asunto(s)
Antibacterianos , Ceftriaxona , Gonorrea , Neisseria gonorrhoeae , Pene , Uretritis , Humanos , Masculino , Gonorrea/diagnóstico , Gonorrea/tratamiento farmacológico , Adulto , Ceftriaxona/uso terapéutico , Ceftriaxona/administración & dosificación , Antibacterianos/uso terapéutico , Antibacterianos/administración & dosificación , Uretritis/microbiología , Uretritis/tratamiento farmacológico , Uretritis/diagnóstico , Neisseria gonorrhoeae/aislamiento & purificación , Pene/microbiología , Resultado del TratamientoRESUMEN
Mycoplasma genitalium (MG) is an emerging sexually transmitted infection, which appears to be a cause of urethritis and cervicitis and has been associated with pelvic inflammatory disease (PID), epididymitis, proctitis, infertility, complications during pregnancy, and human immunodeficiency virus (HIV) transmission. Three Food and Drug Administration (FDA) approved tests are available. Testing should be focused to avoid inappropriate antibiotic use. The Center of Disease Control and Prevention (CDC) guidelines recommend testing for persistent male urethritis, cervicitis, and proctitis and state that testing should be considered in cases of PID. Testing is also recommended for sexual contacts of patients with MG. Testing is not recommended in asymptomatic patients, including pregnant patients, who do not have a history of MG exposure. Although resistance-guided therapy is recommended, there are currently no FDA approved tests for MG macrolide resistance, and tests are not widely available in the United States. The CDC recommends 2-step treatment with doxycycline followed by azithromycin or moxifloxacin. Moxifloxacin is recommended if resistance testing is unavailable or testing demonstrates macrolide resistance..
Asunto(s)
Infecciones por Mycoplasma , Mycoplasma genitalium , Enfermedad Inflamatoria Pélvica , Proctitis , Uretritis , Cervicitis Uterina , Embarazo , Femenino , Humanos , Masculino , Antibacterianos/uso terapéutico , Antibacterianos/farmacología , Uretritis/diagnóstico , Uretritis/tratamiento farmacológico , Uretritis/complicaciones , Moxifloxacino/uso terapéutico , Cervicitis Uterina/complicaciones , Cervicitis Uterina/tratamiento farmacológico , Macrólidos/uso terapéutico , Infecciones por Mycoplasma/diagnóstico , Infecciones por Mycoplasma/tratamiento farmacológico , Infecciones por Mycoplasma/complicaciones , Farmacorresistencia Bacteriana , Enfermedad Inflamatoria Pélvica/diagnóstico , Enfermedad Inflamatoria Pélvica/tratamiento farmacológico , Enfermedad Inflamatoria Pélvica/complicaciones , Proctitis/complicaciones , Proctitis/tratamiento farmacológico , Atención Primaria de SaludRESUMEN
Idiopathic urethritis (IU) is difficult to manage and there is no standarized therapy. The technique of local steroid injection (LSI) for the treatment of IU in children and the results of the patients undergoing LSI from 2020 to 2021 in a single center are presented. Seven patients with IU underwent LSI. An internal urethrotomy was also performed in two patients with stricture. Complete resolution of symptoms and signs occurred in six patients. The remaining patient did not achieve total remission but did substantially improve symptoms. LSI seems to be an effective alternative for treatment of IU in children.
Asunto(s)
Uretritis , Niño , Humanos , Uretritis/tratamiento farmacológico , Uretritis/diagnóstico , Uretra , Terapia Conductista , Recurrencia , EsteroidesRESUMEN
Tyson's glands are sebaceous glands located on each side of the frenulum that communicate with the preputial sac, and their inflammation can be an infrequent complication of urethritis. We describe a rare case that presented with urethral discharge and parafrenular swelling with mucopurulent discharge a week after an unprotected sexual encounter. The patient was empirically treated with 500 mg of ceftriaxone intramuscularly and 100 mg of doxycycline every 12 h for 14 days with symptomatic resolution. The urethral swab culture and the urine polymerase chain reaction (PCR) were negative for Neisseria gonorrhoeae and Chlamydia trachomatis, therefore, and given the response to treatment, nongonococcal tysonitis was diagnosed.
Asunto(s)
Infecciones por Chlamydia , Gonorrea , Uretritis , Humanos , Infecciones por Chlamydia/diagnóstico , Uretritis/diagnóstico , Uretritis/tratamiento farmacológico , Uretritis/etiología , Chlamydia trachomatis , Neisseria gonorrhoeae/genética , Doxiciclina/uso terapéutico , Gonorrea/complicaciones , Gonorrea/diagnóstico , Gonorrea/tratamiento farmacológicoRESUMEN
BACKGROUND: In South Africa, Neisseria gonorrhoeae , which is the predominant cause of male urethritis, is treated syndromically using dual ceftriaxone and azithromycin therapy. We determined antimicrobial susceptibilities of N. gonorrhoeae isolates from urethral discharge specimens, and genetically characterised those with elevated minimum inhibitory concentrations (MICs) for first-line antimicrobials. METHODS: Routine antimicrobial susceptibility testing (AST) of N. gonorrhoeae isolates included E-test for ceftriaxone, cefixime and gentamicin and agar dilution for azithromycin and spectinomycin. Neisseria gonorrhoeae Sequence Typing for Antimicrobial Resistance (NG-STAR) was performed for isolates with elevated MICs to identify antimicrobial resistance (AMR) determinants, and Neisseria gonorrhoeae Multi-Antigen Sequence Typing (NG-MAST) was used to determine strain relatedness. RESULTS: N. gonorrhoeae was cultured from urethral discharge swab specimens obtained from 196 of 238 (82.4%) men presenting to a primary healthcare facility in Johannesburg in 2021. All viable isolates were susceptible to extended-spectrum cephalosporins. Four isolates had high azithromycin MICs ranging from 32mg/L to >256mg/L and grouped into two novel NG-MAST and NG-STAR groups. Two isolates from Group 1 (NG-MAST ST20366, NG-STAR ST4322) contained mutated mtrR (G45D) and 23S rRNA (A2059G) alleles, while the two isolates from Group 2 (NG-MAST ST20367, NG-STAR ST4323) had different mutations in mtrR (A39T) and 23S rRNA (C2611T). CONCLUSIONS: We report the first cases of high-level azithromycin resistance in N. gonorrhoeae from South Africa. Continued AMR surveillance is critical to detect increasing azithromycin resistance prevalence in N. gonorrhoeae , which may justify future modifications to the STI syndromic management guidelines.
Asunto(s)
Gonorrea , Uretritis , Masculino , Humanos , Femenino , Azitromicina/farmacología , Azitromicina/uso terapéutico , Neisseria gonorrhoeae/genética , Antibacterianos/farmacología , Antibacterianos/uso terapéutico , Ceftriaxona/farmacología , Ceftriaxona/uso terapéutico , Gonorrea/tratamiento farmacológico , Gonorrea/epidemiología , Sudáfrica , ARN Ribosómico 23S/genética , Uretritis/tratamiento farmacológico , Farmacorresistencia Bacteriana/genéticaRESUMEN
BACKGROUND: Mycoplasma genitalium (MG) is an emerging sexually transmitted infection. Treatment of MG is complicated by increasing resistance to primary treatment regimens, including macrolides and fluoroquinolones. Understanding the various clinical presentations and relative effectiveness of treatments for MG is crucial to optimizing care. METHODS: Patients with a positive MG nucleic acid amplification test between July 1, 2019, and June 30, 2021, at a large health system in New York City were included in a retrospective cohort. Demographics, clinical presentations, coinfections, treatment, and follow-up microbiologic tests were obtained from the electronic medical record. Associations with microbiologic cure were evaluated in bivariate and multivariable logistic regression models. RESULTS: Five hundred two unique patients had a positive MG nucleic acid amplification test result during the study period. Male individuals presented predominantly with urethritis (117 of 187 [63%]) and female individuals with vaginal symptoms (142 of 315 [45%]). Among patients with follow-up testing who received a single antibiotic at the time of treatment, 43% (90 of 210) had persistent infection and 57% (120 of 210) had microbiologic cure. Eighty-two percent of patients treated with moxifloxacin had microbiologic cure compared with 41% of patients receiving azithromycin regimens ( P < 0.001). In multivariable analysis, treatment with moxifloxacin was associated with 4 times the odds of microbiologic cure relative to low-dose azithromycin (adjusted odds ratio [aOR], 4.18; 95% confidence interval, 1.73-10.13; P < 0.01). CONCLUSIONS: Clinical presentations of MG vary, with urethritis or vaginal symptoms in most cases. Among patients who received a single antibiotic, only treatment with moxifloxacin was significantly associated with microbiologic cure relative to low-dose azithromycin.
Asunto(s)
Infecciones por Mycoplasma , Mycoplasma genitalium , Uretritis , Humanos , Masculino , Femenino , Azitromicina/uso terapéutico , Infecciones por Mycoplasma/diagnóstico , Infecciones por Mycoplasma/tratamiento farmacológico , Infecciones por Mycoplasma/epidemiología , Moxifloxacino/uso terapéutico , Uretritis/diagnóstico , Uretritis/tratamiento farmacológico , Uretritis/epidemiología , Estudios Retrospectivos , Ciudad de Nueva York/epidemiología , Antibacterianos/uso terapéutico , Antibacterianos/farmacología , Resultado del Tratamiento , Macrólidos/uso terapéutico , Atención a la Salud , Farmacorresistencia BacterianaRESUMEN
Mycoplasma genitalium (MG) is a common cause of non-gonococcal urethritis, but a role in acute or chronic prostatitis has not been described. We describe the case of a 42-year-old man with recurrent urinary tract infections since 2018 who developed chronic prostatitis despite several and prolonged antibiotic courses. Multiparametric prostatic magnetic resonance showed peripheral inflammatory alterations. A 4-glass Meares-Stamey test detected MG in the third voided bladder (VB3) sample. Moxifloxacin 400 mg daily for 28 days resulted in sustained clinical and microbiological cure.
Asunto(s)
Infecciones por Mycoplasma , Mycoplasma genitalium , Prostatitis , Uretritis , Masculino , Humanos , Adulto , Prostatitis/diagnóstico , Prostatitis/tratamiento farmacológico , Antibacterianos/uso terapéutico , Uretritis/diagnóstico , Uretritis/tratamiento farmacológico , Uretritis/microbiología , Enfermedad Crónica , Infecciones por Mycoplasma/complicaciones , Infecciones por Mycoplasma/diagnóstico , Infecciones por Mycoplasma/tratamiento farmacológicoRESUMEN
The study evaluated the prevalence of gonorrhoea and chlamydia infections and find out other non-infectious diseases in sexually active young males with urethritis-like symptoms and their treatment outcomes. We retrospectively reviewed the young adult males (aged 20-50 years) who visited our clinic with urethritis symptoms from March 2019 to April 2022. All patients underwent urinalysis, urine culture, and urinary polymerase chain reaction (PCR) testing for gonorrhoea and chlamydia. Student's t-test and Pearson's chi-square test were used to compare the differences between the triple-negative group (i.e., negative results in urinalysis, urine culture, and urinary PCR) and the any-positive group. Logistic regression analyses were used to evaluate the predictive factors for positive PCR results for gonorrhoea or chlamydia in patients with negative urinalysis and urine culture. Of the 365 participants with urethritis-like symptoms, 139 patients were diagnosed of gonococcal or chlamydia urethritis. Among the 202 patients with negative urinalysis and urine culture, 60 patients were diagnosed with gonorrhoea or chlamydia using PCR. Urethral discharge was an independent predictor. 142 patients with triple negative results were attributed to other non-infectious diseases. Empirical antibiotic treatment is recommended for patients with urethritis symptoms showing positive or negative urinalysis results but with urethral discharge.
Asunto(s)
Infecciones por Chlamydia , Gonorrea , Enfermedades no Transmisibles , Uretritis , Masculino , Adulto Joven , Humanos , Uretritis/diagnóstico , Uretritis/tratamiento farmacológico , Uretritis/epidemiología , Gonorrea/diagnóstico , Gonorrea/tratamiento farmacológico , Gonorrea/epidemiología , Estudios Retrospectivos , Chlamydia trachomatis , Infecciones por Chlamydia/diagnóstico , Infecciones por Chlamydia/tratamiento farmacológico , Infecciones por Chlamydia/epidemiología , Resultado del TratamientoRESUMEN
Haemophilus parainfluenzae is a commensal organism with rising numbers of multidrug-resistant (MDR) strains. This pathogen is of increasing clinical relevance in urogenital infection. The aim of this work was to identify and characterise the molecular mechanisms of resistance associated with four cephalosporin-resistant H. parainfluenzae strains collected from patients with urethritis. Antimicrobial resistance was determined by microdilution following European Committee on Antimicrobial Susceptibility Testing criteria. Strains were then analysed by whole-genome sequencing to determine clonal relationship and the molecular basis of antimicrobial resistance. Finally, a phylogenetic analysis was performed on all urogenital MDR strains of H. parainfluenzae previously isolated in our hospital. All strains were resistant to ß-lactams, macrolides, tetracycline, fluoroquinolones, chloramphenicol, cotrimoxazole, and aminoglycosides. The resistance profile was compatible with the presence of an extended-spectrum ß-lactamase (ESBL). Whole-genome sequencing detected blaCTX-M-15 that conferred high minimum inhibitory concentrations to cephalosporins in two novel integrative and conjugative elements (ICEHpaHUB6 and ICEHpaHUB7) that also harboured a blaTEM-1 ß-lactamase. This study shows a novel blaCTX-M-15 ESBL carried in an integrative conjugative element in four extensively drug-resistant H. parainfluenzae strains. This resistance determinant could be transmitted to other sexually transmitted pathogens and this is a cause for concern.
Asunto(s)
Haemophilus parainfluenzae , Uretritis , Humanos , Haemophilus parainfluenzae/genética , Uretritis/tratamiento farmacológico , Filogenia , Antibacterianos/farmacología , Antibacterianos/uso terapéutico , Cefalosporinas/farmacología , beta-Lactamasas/genética , Pruebas de Sensibilidad MicrobianaRESUMEN
Neisseria gonorrhoeae is one of the important pathogens of sexually transmitted infections. N. gonorrhoeae is rapidly becoming antimicrobial resistant, and there are few drugs that are effective in the initial treatment of gonorrhea. To understand the trends of antimicrobial susceptibility of N. gonorrhoeae, the Surveillance Committee of the Japanese Society of Infectious Diseases, the Japanese Society for Chemotherapy, and the Japanese Society of Clinical Microbiology conducted the third nationwide antimicrobial susceptibility surveillance of N. gonorrhoeae isolated from male urethritis. The specimens were collected from male patients with urethritis at 30 facilities from May 2016 to July 2017. From the 159 specimens collected, 87 N. gonorrhoeae strains were isolated, and 85 were tested for susceptibility to 21 antimicrobial agents. All strains were non-susceptible to penicillin G. Seven strains (8.2%) were ß-lactamase-producing strains. The rates of susceptibility to cefixime and cefpodoxime were 96.5% and 52.9%, respectively. Three strains were non-susceptible with a minimum inhibitory concentration (MIC) of 0.5 mg/L for cefixime. None of the strains were resistant to ceftriaxone or spectinomycin. The susceptibility rate for ciprofloxacin was 23.5% (20 strains), and no strains showed intermediate susceptibility. The susceptibility rate against azithromycin was 81.2%, with one strain isolated with a MIC of 8 mg/L against azithromycin. The results of this surveillance indicate that ceftriaxone and spectinomycin, which are currently recommended for gonococcal infections in Japan, appear to be effective. It will be necessary to further expand the scale of the next surveillance to understand the current status of drug-resistant N. gonorrhoeae in Japan.
Asunto(s)
Antiinfecciosos , Gonorrea , Uretritis , Humanos , Masculino , Neisseria gonorrhoeae , Antibacterianos/farmacología , Antibacterianos/uso terapéutico , Cefixima/farmacología , Cefixima/uso terapéutico , Ceftriaxona/uso terapéutico , Azitromicina/uso terapéutico , Espectinomicina/farmacología , Espectinomicina/uso terapéutico , Uretritis/tratamiento farmacológico , Uretritis/epidemiología , Uretritis/microbiología , Japón/epidemiología , Gonorrea/tratamiento farmacológico , Gonorrea/epidemiología , Antiinfecciosos/uso terapéutico , Pruebas de Sensibilidad MicrobianaRESUMEN
OBJECTIVES: To examine the time required to suppress HIV in the genital tract with antiretroviral therapy (ART) in men with urethritis. DESIGN: An observational cohort study. METHODS: Men with HIV and urethritis not on ART were enrolled at an STI clinic in Malawi and offered to initiate ART. Blood and semen samples were collected pretreatment and at 1, 2, 4, 8, 12 and 24âweeks posturethritis treatment. Median viral loads (VLs) were calculated by ART initiation groups: 'within 1 week', 'between 1 and 4 weeks' and 'no ART before 4 weeks', based on the men's choice about whether or not to initiate ART. The presence of ART at each visit was confirmed by bioanalytical methods. FINDINGS: Between January 2017 and November 2018, 74 men presented with urethritis and HIV and were confirmed ART naive. The median age was 32âyears. Forty-one (55% of men) initiated ART within 1âweek; 12 (16%) between 1 and 4âweeks; and 21 (28%) did not initiate ART by week 4. Within the 1âweek group, median VL was suppressed within 4âweeks in both semen and blood. Among the 1-4âweeks group, VL was suppressed within 4âweeks in semen and 5âweeks in blood. Among the no ART before 4âweeks group, VL in semen declined within the first 4âweeks but remained unsuppressed through week 24, and there was no significant decline in blood HIV. CONCLUSION: Treatment of urethritis and prompt initiation of ART with counseling for safer sex for at least one month is a critical measure to reduce transmission of HIV.
Asunto(s)
Fármacos Anti-VIH , Infecciones por VIH , VIH-1 , Uretritis , Masculino , Humanos , Adulto , Infecciones por VIH/tratamiento farmacológico , Semen , Uretritis/tratamiento farmacológico , Estudios de Cohortes , Carga Viral , Fármacos Anti-VIH/uso terapéuticoRESUMEN
BACKGROUND: Mycoplasma genitalium (MG) is on the CDC Watch List of Antimicrobial Resistance Threats, yet there is no systematic surveillance to monitor change. METHODS: We initiated surveillance in sexual health clinics in 6 cities, selecting a quota sample of urogenital specimens tested for gonorrhea and/or chlamydia. We abstracted patient data from medical records and detected MG and macrolide-resistance mutations (MRMs) by nucleic acid amplification testing. We used Poisson regression to estimate adjusted prevalence ratios (aPRs) and 95% CIs, adjusting for sampling criteria (site, birth sex, symptom status). RESULTS: From October-December 2020 we tested 1743 urogenital specimens: 57.0% from males, 46.1% from non-Hispanic Black persons, and 43.8% from symptomatic patients. MG prevalence was 16.6% (95% CI: 14.9-18.5%; site-specific range: 9.9-23.5%) and higher in St Louis (aPR: 1.9; 1.27-2.85), Greensboro (aPR: 1.8; 1.18-2.79), and Denver (aPR: 1.7; 1.12-2.44) than Seattle. Prevalence was highest in persons <18 years (30.4%) and declined 3% per each additional year of age (aPR: .97; .955-.982). MG was detected in 26.8%, 21.1%, 11.8%, and 15.4% of urethritis, vaginitis, cervicitis, and pelvic inflammatory disease (PID), respectively. It was present in 9% of asymptomatic males and 15.4% of asymptomatic females, and associated with male urethritis (aPR: 1.7; 1.22-2.50) and chlamydia (aPR: 1.7; 1.13-2.53). MRM prevalence was 59.1% (95% CI: 53.1-64.8%; site-specific range: 51.3-70.6%). MRMs were associated with vaginitis (aPR: 1.8; 1.14-2.85), cervicitis (aPR: 3.5; 1.69-7.30), and PID cervicitis (aPR: 1.8; 1.09-3.08). CONCLUSIONS: MG infection is common in persons at high risk of sexually transmitted infections; testing symptomatic patients would facilitate appropriate therapy. Macrolide resistance is high and azithromycin should not be used without resistance testing.
Asunto(s)
Infecciones por Mycoplasma , Mycoplasma genitalium , Enfermedad Inflamatoria Pélvica , Salud Sexual , Uretritis , Cervicitis Uterina , Vaginitis , Femenino , Humanos , Masculino , Antibacterianos/farmacología , Antibacterianos/uso terapéutico , Uretritis/tratamiento farmacológico , Mycoplasma genitalium/genética , Cervicitis Uterina/tratamiento farmacológico , Macrólidos/farmacología , Macrólidos/uso terapéutico , Farmacorresistencia Bacteriana , Enfermedad Inflamatoria Pélvica/tratamiento farmacológico , Vaginitis/tratamiento farmacológico , Infecciones por Mycoplasma/diagnóstico , PrevalenciaRESUMEN
INTRODUCTION: With the advancement of microbiological methods, the isolation of less typical pathogens in cases of urethral and rectal infection is more frequent, apart from the classic etiological agents. One of them is formed by species of Haemophilus no ducreyi (HND). The objective of this work is to describe frequency, susceptibility to antibiotics, and clinical features of HDN urethritis and proctitis in adult males. PATIENTS AND METHODS: This is an observational retrospective descriptive study of the results obtained by the Microbiology laboratory of the Virgen de las Nieves University Hospital on the isolates of HND in genital and rectal samples from males between 2016 and 2019. RESULTS: HND was isolated in 135 (7%) of the genital infection episodes diagnosed in men. H. parainfluenzae was the most commonly isolated (34/45; 75.6%). The most frequent symptoms in men with proctitis were rectal tenesmus (31.6%) and lymphadenopathy (10.5%); in those with urethritis, dysuria (71.6%), urethral suppuration (46.7%) and gland lesions (27%), so differentiating it from infections caused by other genitopathogens is difficult. 43% of patients were HIV positive. Antibiotic resistance rates for H. parainfluenzae were high to quinolons, ampicillin, tetracycline and macrolides. CONCLUSION: HND species should be considered as possible etiologic agents in episodes of urethral and rectal infection in men, especially in cases with negative screening tests for agents that cause sexually transmitted infections (STIs). Its microbiological identification is essential for the establishment of an effective targeted treatment.
Asunto(s)
Haemophilus ducreyi , Proctitis , Uretritis , Masculino , Adulto , Humanos , Uretritis/tratamiento farmacológico , Estudios Retrospectivos , Haemophilus , Uretra/microbiologíaRESUMEN
Sexually transmitted infection (STI) rates in the U.S. have rapidly increased in the past decade. Although most of this rise is due to syphilis, gonorrhea, and chlamydia, less common STIs are also rising, including Mycoplasma genitalium. We present the case of a 40-year-old male with a history of virologically-suppressed human immunodeficiency virus (HIV) infection who presented with recurrent nongonococcal urethritis. Unfortunately, his symptoms were refractory to multiple empiric drug regimens, and he was eventually diagnosed with Mycoplasma genitalium. After consultation with the Centers for Disease Control and Prevention STI branch, minocycline was successfully used to eradicate the infection.
Asunto(s)
Infecciones por VIH , Infecciones por Mycoplasma , Mycoplasma genitalium , Uretritis , Estados Unidos , Masculino , Humanos , Adulto , Uretritis/tratamiento farmacológico , Infecciones por Mycoplasma/diagnóstico , Infecciones por Mycoplasma/tratamiento farmacológico , MinociclinaRESUMEN
Queyrat erythroplasia is an intraepidermal squamous cell carcinoma localized on the glans penis or the inner side of the foreskin. It accounts for about 10% of all penile malignancies and up to 33% cases may lead to invasive squamous cell carcinoma and the intraurethral erythroplasia of Queyrat is relatively rare. Treatment of Queyrat erythroplasia present a challenge especially if the proximal urethra is involved. Here, we report a case of intractable Queyrat erythroplasia involving the urethral meatus. This case suggested that 5-aminolaevulinic acid photodynamic therapy is effective and safe in the treatment of Queyrat erythroplasia, which provides a new choice for the patients with Queyrat erythroplasia with poor therapeutic effect.